2026-04-13T15:13:10Zhttps://recercat.cat/oai/request

oai:recercat.cat:2072/4802162025-08-31T17:31:12Zcom_2072_98col_2072_378192

Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors : Position statement of the AEEH-AEG-SEPD-SEOM-GETECCU Riveiro Barciela, Mar Carballal, Sabela Diaz-Gonzalez, Álvaro Mañosa i Ciria, Míriam Gallego-Plazas, Javier Cubiella, Joaquín Jimenez-Fonseca, Paula Varela, María Menchen, Luís Sangro, Bruno Fernandez-Montes, Ana Mesonero, Francisco Rodriguez-Gandia, Miguel Ángel Rivera, Fernando Londono, María-Carlota Immunotherapy Immune checkpoint inhibitors Toxicity Hepatitis Colitis Drug-induced liver injury Immune-related adverse events Diarrhea The development of the immune checkpoint inhibitors (ICI) is one of the most remarkable achievements in cancer therapy in recent years. However, their exponential use has led to an increase in immune-related adverse events (irAEs). Gastrointestinal and liver events encompass hepatitis, colitis and upper digestive tract symptoms accounting for the most common irAEs, with incidence rates varying from 2 % to 40 %, the latter in patients undergoing combined ICIs therapy. Based on the current scientific evidence derived from both randomized clinical trials and real-world studies, this statement document provides recommendations on the diagnosis, treatment and prognosis of the gastrointestinal and hepatic ICI-induced adverse events. 2024 Ressenya Revista Española de Enfermedades Digestivas ; Vol. 116 Núm. 2 (2024), p. 83-113 open access Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades. https://creativecommons.org/licenses/by-nc-nd/4.0/